Clinical Trial

Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases.

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A new radiotracer, 68Ga-FXX489 (NNS309), has been developed for tracking fibroblast activation protein (FAP) and visualizing the tumor stroma. The purpose of the study is to explore the diagnostic value of 68Ga-FXX489 (NNS309) PET/CT imaging in oncological diseases, to assess its safety, imaging characteristics, and biodistribution after administration.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-20.
Status change: Not Yet Recruiting → Recruiting 2026-03-30
Trial Details
NCT Number NCT07144085
Lead Sponsor Yi Tian
Conditions Tumor, Metastatic Cancer
Enrollment 30 participants
Start Date 2025-09-11
Primary Completion 2027-07-30 (estimated)
Study Completion 2027-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-03